





















# Reference Data

---

# Business segments and major products

Segment	Description	Major products				
<b>Imaging Products Business</b>	<b>Digital camera-interchangeable lens type</b> <b>Interchangeable lens</b> <b>Cinema camera</b>	 Mirrorless Camera [Z6III]	 Mirrorless Camera [Zf]	 [NIKKOR Z 28-400mm f/4-8 VR]	 [V-RAPTOR XL [X]]	
<b>Precision Equipment Business</b>	<b>FPD lithography system</b> <b>Semiconductor lithography system</b> <b>Alignment station</b> <b>Measuring &amp; inspection system</b>	 FPD Lithography System [FX-88S]	 ArF Immersion Scanner [NSR-S636E]	 Alignment Station [Litho Booster]	 Automatic Macro Inspection System [AMI-5700]	
<b>Healthcare Business</b>	<b>Biological microscope</b> <b>Retinal diagnostic imaging system</b> <b>Contract Cell Manufacturing business</b>	 Confocal Microscope System [AX/AX R]	 Ultra-Widefield Retinal Diagnostic Imaging System with Integrated UWF-Guided Swept Source OCT [Silverstone]	 Contract Cell Manufacturing		
<b>Components Business</b>	<b>EUV related component</b> <b>Optical parts, Optical components</b> <b>Encoders, Measuring instrument</b> <b>Photomask substrate for FPD</b>	 Optical Parts	 Optical Components	 Multi-turn External Battery-Free Absolute Encoder [MAR-M700MFA]	 Versatile Large-Envelop X-ray and CT System [VOXLS 40 C 450]	 Photomask Substrates for FPD
<b>Digital Manufacturing Business</b>	<b>Metal 3D printer</b> <b>Optical processing machine</b> <b>3D scanner</b> <b>Contract material processing</b>	 Metal 3D Printer [NXG XII 600E]	 Material Processing Machine [Lasermeister LM300A]	 3D Scanner [Lasermeister SB100]	 Contract Material Processing	

# Forecast for the year ending March 31, 2025: Financial Highlights

Billions of Yen	FY2022/3	FY2023/3	FY2024/3			FY2025/3 Forecast		
	Full Year	Full Year	1H	2H	Full Year	1H	2H	Full Year
<b>Revenue</b>	539.6	628.1	331.2	386.0	717.2	<b>346.0</b>	<b>404.0</b>	<b>750.0</b>
<b>Operating profit</b>	49.9	54.9	13.6	26.1	39.7	<b>7.0</b>	<b>28.0</b>	<b>35.0</b>
% vs Revenue	9.3%	8.7%	4.1%	6.8%	5.5%	<b>2.0%</b>	<b>6.9%</b>	<b>4.7%</b>
<b>Profit before tax</b>	57.0	57.0	15.2	27.4	42.6	<b>10.0</b>	<b>30.0</b>	<b>40.0</b>
% vs Revenue	10.6%	9.1%	4.6%	7.1%	5.9%	<b>2.9%</b>	<b>7.4%</b>	<b>5.3%</b>
<b>Profit attributable to owners of parent</b>	42.6	44.9	9.8	22.7	32.5	<b>7.0</b>	<b>23.0</b>	<b>30.0</b>
% vs Revenue	7.9%	7.2%	3.0%	5.9%	4.5%	<b>2.0%</b>	<b>5.7%</b>	<b>4.0%</b>
<b>FCF</b>	30.9	-112.1		-10.6				-
<b>ROE</b>	7.5%	7.4%		5.0%			<b>4.3%</b>	
<b>EPS</b>	¥116.23	¥125.46		¥94.03			<b>¥86.59</b>	
<b>Annual Dividends</b>	¥40	¥45		¥50			<b>¥55</b>	
Exchange Rate: US\$	¥112	¥135	¥141	¥148	¥145	<b>¥150</b>	<b>¥145</b>	<b>¥148</b>
EURO	¥131	¥141	¥153	¥160	¥157	<b>¥161</b>	<b>¥155</b>	<b>¥158</b>

Note: The numbers of issued shares assumed for EPS forecast calculation: approx. 346.5M shares

# Forecast for the year ending March 31, 2025: Financial Highlights

Billions of Yen	FY2024/3			FY2025/3 Forecast			Change		
	Actual (A)			Forecast (B)			(B)-(A)		
	1H	2H	Full Year	1H	2H	Full Year	1H	2H	Full Year
<b>Revenue</b>	331.2	386.0	717.2	<b>346.0</b>	<b>404.0</b>	<b>750.0</b>	+14.8	+18.0	+32.8
<b>Operating profit</b>	13.6	26.1	39.7	<b>7.0</b>	<b>28.0</b>	<b>35.0</b>	-6.6	+1.9	-4.7
% vs Revenue	4.1%	6.8%	5.5%	<b>2.0%</b>	<b>6.9%</b>	<b>4.7%</b>	-2.1P	+0.1P	-0.8P
<b>Profit before tax</b>	15.2	27.4	42.6	<b>10.0</b>	<b>30.0</b>	<b>40.0</b>	-5.2	+2.6	-2.6
% vs Revenue	4.6%	7.1%	5.9%	<b>2.9%</b>	<b>7.4%</b>	<b>5.3%</b>	-1.7P	+0.3P	-0.6P
<b>Profit attributable to owners of parent</b>	9.8	22.7	32.5	<b>7.0</b>	<b>23.0</b>	<b>30.0</b>	-2.8	+0.3	-2.5
% vs Revenue	3.0%	5.9%	4.5%	<b>2.0%</b>	<b>5.7%</b>	<b>4.0%</b>	-1.0P	-0.2P	-0.5P
<b>ROE</b>	5.0%			<b>4.3%</b>			-0.7P		
<b>EPS</b>	¥94.03			<b>¥86.59</b>			-¥7.44		
<b>Annual Dividends</b>	¥50			<b>¥55</b>			+¥5		
Exchange Rate: US\$	¥141	¥148	¥145	<b>¥150</b>	<b>¥145</b>	<b>¥148</b>	+¥9	-¥3	+¥3
EURO	¥153	¥160	¥157	<b>¥161</b>	<b>¥155</b>	<b>¥158</b>	+¥8	-¥5	+¥1

Note: The numbers of issued shares assumed for EPS forecast calculation: approx. 346.5M shares

# Forecast for the year ending March 31, 2025: Performance by Segment

Billions of Yen		FY2024/3 Actual (A)			FY2025/3 Forecast (B)			Change (B)-(A)		
		1H	2H	Full Year	1H	2H	Full Year	1H	2H	Full Year
Imaging Products Business	Revenue	137.6	142.1	279.7	<b>155.0</b>	<b>150.0</b>	<b>305.0</b>	+17.4	+7.9	+25.3
	Operating profit	25.2	21.3	46.5	<b>25.0</b>	<b>20.0</b>	<b>45.0</b>	-0.2	-1.3	-1.5
Precision Equipment Business	Revenue	96.0	123.3	219.3	<b>90.0</b>	<b>125.0</b>	<b>215.0</b>	-6.0	+1.7	-4.3
	Operating profit	3.2	11.9	15.1	<b>4.0</b>	<b>11.0</b>	<b>15.0</b>	+0.8	-0.9	-0.1
Healthcare Business	Revenue	51.2	56.6	107.8	<b>53.0</b>	<b>62.0</b>	<b>115.0</b>	+1.8	+5.4	+7.2
	Operating profit	2.7	2.6	5.3	<b>1.5</b>	<b>8.5</b>	<b>10.0</b>	-1.2	+5.9	+4.7
Components Business	Revenue	36.6	49.3	85.9	<b>34.0</b>	<b>51.0</b>	<b>85.0</b>	-2.6	+1.7	-0.9
	Operating profit	5.1	10.0	15.1	<b>4.0</b>	<b>13.0</b>	<b>17.0</b>	-1.1	+3.0	+1.9
Digital Manufacturing Business	Revenue	8.2	12.8	21.0	<b>13.0</b>	<b>15.0</b>	<b>28.0</b>	+4.8	+2.2	+7.0
	Operating profit	-8.7	-5.3	-14.0	<b>-6.0</b>	<b>-3.5</b>	<b>-9.5</b>	+2.7	+1.8	+4.5
Others	Revenue	1.4	1.8	3.2	<b>1.0</b>	<b>1.0</b>	<b>2.0</b>	-0.4	-0.8	-1.2
	Operating profit	0.1	4.3	4.4	<b>0.0</b>	<b>2.5</b>	<b>2.5</b>	-0.1	-1.8	-1.9
Corporate expenses, etc.	Operating profit	-14.1	-18.7	-32.8	<b>-21.5</b>	<b>-23.5</b>	<b>-45.0</b>	-7.4	-4.8	-12.2
	Broken out: Expense related to investment in growth	-10.2	-10.7	-20.9	<b>-9.0</b>	<b>-11.0</b>	<b>-20.0</b>	+1.2	-0.3	+0.9
	Broken out: Expense for administration department	-6.8	-8.0	-14.8	<b>-12.5</b>	<b>-10.5</b>	<b>-23.0</b>	-5.7	-2.5	-8.2
	Broken out: Elimination of intersegment transactions	2.9	0.0	2.9	<b>0.0</b>	<b>-2.0</b>	<b>-2.0</b>	-2.9	-2.0	-4.9
Consolidated	Revenue	331.2	386.0	717.2	<b>346.0</b>	<b>404.0</b>	<b>750.0</b>	+14.8	+18.0	+32.8
	Operating profit	13.6	26.1	39.7	<b>7.0</b>	<b>28.0</b>	<b>35.0</b>	-6.6	+1.9	-4.7

Note: FY2024/3 results have been re-stated to reflect segmentation changes.


# 1st quarter of the year ending March 31, 2025: Quarterly Performance by Segment

Billions of Yen		FY2024/3				FY2025/3
		Q1	Q2	Q3	Q4	Q1
Imaging Products Business	Revenue	74.4	63.2	84.3	57.8	<b>83.7</b>
	Operating profit	15.3	9.9	17.7	3.6	<b>17.8</b>
Precision Equipment Business	Revenue	37.3	58.7	58.5	64.8	<b>33.1</b>
	Operating profit	-3.6	6.8	7.9	4.0	<b>-2.1</b>
Healthcare Business	Revenue	25.2	26.0	25.6	31.0	<b>26.2</b>
	Operating profit	1.8	0.9	0.2	2.4	<b>-0.6</b>
Components Business	Revenue	16.0	20.6	22.7	26.6	<b>13.8</b>
	Operating profit	1.3	3.8	5.6	4.4	<b>-0.1</b>
Digital Manufacturing Business	Revenue	4.3	3.9	5.7	7.1	<b>5.9</b>
	Operating profit	-3.7	-5.0	-3.2	-2.1	<b>-3.5</b>
Others	Revenue	0.6	0.8	0.9	0.9	<b>1.0</b>
	Operating profit	-0.0	0.1	1.7	2.6	<b>0.2</b>
Corporate expenses, etc.	Operating profit	-7.8	-6.3	-9.2	-9.5	<b>-8.7</b>
	Broken out: Expense related to investment in growth	-5.1	-5.1	-5.1	-5.6	<b>-4.9</b>
	Broken out: Expense for administration department	-3.4	-3.4	-3.5	-4.5	<b>-3.7</b>
	Broken out: Elimination of intersegment transactions	0.7	2.2	-0.6	0.6	<b>-0.0</b>
Consolidated	Revenue	158.1	173.1	197.7	188.3	<b>163.8</b>
	Operating profit	3.2	10.4	20.8	5.3	<b>2.9</b>


Note: FY2024/3 results have been re-stated to reflect segmentation changes.

# 1st quarter of the year ending March 31, 2025: Financial Position

## ASSET



## LIABILITIES/EQUITY




Equity ratio 58.6% 58.1% 59.6% 59.0%

Note: Equity ratio is the ratio of equity attributable to owners of parent to total assets.  
Cash and cash equivalents excludes time deposits with maturities of three months or more.


# Capital Expenditures, Depreciation & Amortization, and Inventories

### CAPITAL EXPENDITURES, DEPRECIATION & AMORTIZATION



■ Capital expenditures ■ Depreciation & amortization

### BREAKDOWN OF INVENTORIES




Note: Capital expenditures include right-of-use assets.  
 Depreciation & amortization includes right-of-use assets, depreciation of property, plant and equipment and amortization of intangible assets obtained by business combination.  
 Inventories of FY2024/3 results have been re-stated to reflect segmentation changes.



# 1st quarter of the year ending March 31, 2025: Revenue Breakdown


## BY SEGMENT

Billions of Yen



## BY REGION


Billions of Yen




Note: The outside and inside circles show the breakdown of FY2025/3 revenue of ¥163.8B and FY2024/3 revenue of ¥158.1B, respectively. FY2024/3 results have been re-stated to reflect segmentation changes.

# Forecast for the year ending March 31, 2025: R&D Expenditures

## R&D EXPENDITURES




## R&D EXPENDITURES BREAKDOWN



Note: R&D expenditures includes capitalization of some development expenditures.  
Due to segment revision from FY2025/3, the financial figures for FY2024/3 are displayed according to the reorganized display.


# Cash Flow History



Note: FCF + CF from financial activities + Effect of exchange rate changes on cash and cash equivalents = net increase (decrease) in cash and cash equivalents


# Imaging Products Business: Sales Units

## SALES IN UNITS BY PRODUCT CATEGORY




# Forecast for the year ending March 31, 2025: Precision Equipment Business Sales Units

**FPD LITHOGRAPHY SYSTEMS SALES  
BY GENERATION**




**SEMICONDUCTOR LITHOGRAPHY  
SYSTEMS SALES BY TECHNOLOGY  
(INCL. REFURBISHED)**



Note: "i-line, etc." part in numbers of semiconductor lithography systems sales include sales numbers of the "Mini Step & Repeat Exposure System."  
The unit sales of new semiconductor lithography systems are 23 units in FY2021/3, 17 units in FY2022/3, 27 units in FY2023/3, 31 units in FY2024/3, and 24 units (forecast) in FY2025/3.


# Precision Equipment Business: Sales Units

**FPD LITHOGRAPHY SYSTEMS SALES IN UNITS BY GENERATION**



# Precision Equipment Business: Sales Units

## SEMICONDUCTOR LITHOGRAPHY SYSTEMS SALES IN UNITS BY TECHNOLOGY (INCL. REFURBISHED)



Note: "i-line, etc." part in numbers of semiconductor lithography systems sales include sales numbers of the "Mini Step & Repeat Exposure System."

# Forecast for the year ending March 31, 2025: R&D Expenditures Foreign Exchange Impact

	Exchange Rate	Financial Impact from Fluctuation by 1 yen	
	FY2025/3 Forecast for Q2~Q4	Revenue Q2~Q4	Operating Profit Q2~Q4
US \$	¥145	Approx. ¥1.3B	Approx. ¥0.3B
EURO	¥155	Approx. ¥0.5B	Approx. ¥0.2B

Note: The foreign exchange impact above is made on the assumption that emerging-market currencies move according to the influence of US\$ and EURO.



# Revision of Business Segment (From FY2025/3)

<u>Old Segment</u>	<u>Business Unit (BU)</u>		<u>Business Unit (BU)</u>	<u>New Segment</u>
Imaging Products	Imaging Products BU		Imaging Products BU	Imaging Products
Precision Equipment	Precision Equipment Group	FPD Lithography BU	FPD Lithography BU	Precision Equipment
		Semiconductor Lithography BU	Semiconductor Lithography BU	
Healthcare	Healthcare BU		Healthcare BU	Healthcare
Components	Customized Products BU		Customized Products BU	Components
	Glass BU		Glass BU	
	Digital Solutions BU		Industrial Solutions BU	
Digital Manufacturing	Industrial Metrology BU		Advanced Manufacturing BU	Digital Manufacturing
	Advanced Manufacturing BU			
Others	Others		Others	Others
Corporate expenses, etc.	Headquarters division of the parent company		Headquarters division of the parent company	Corporate expenses, etc.



Former Industrial Metrology BU to be disclosed as a part of the Components Business.  
 The Digital Manufacturing Business is comprised solely the Advanced Manufacturing BU.

## Disclaimer Regarding Forecast and Projections

---

Forward-looking statements for earnings and other performance data contained herein are based on information currently available to the Company, and all potential risks and uncertainties are taken into account. The Company asks that investors understand that changes in conditions may cause actual performance to significantly differ from these projections.

